Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations of Misrepresentation - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide to customers [4]. - The company also purportedly stated that its sale of compounded semaglutide complied with FDA regulations [4]. Group 4: Stock Market Reaction - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 to $41.98 [5].

Core Points - Rosen Law Firm is reminding purchasers of Hims & Hers Health, Inc. common stock of the lead plaintiff deadline for a class action lawsuit, which is August 25, 2025 [1] - Investors who purchased Hims common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] Company Details - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [4] - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo, which would ensure continued access to Wegovy, and that positive statements were made about the partnership while omitting critical details [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors [3]

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3] Group 1: Company Actions and Allegations - Hims & Hers is accused of making materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk during the class period from April 29, 2025, to June 22, 2025 [3] - The termination of the partnership with Novo Nordisk led to a significant decline in Hims & Hers' stock price, dropping over 34% in intraday trading, indicating investor concerns about regulatory compliance and reputational risks [2] Group 2: Legal Proceedings - Berger Montague is investigating potential securities fraud claims against Hims & Hers, with a deadline for investors to seek lead plaintiff status by August 25, 2025 [1] - The investigation focuses on whether Hims & Hers and certain executives violated federal securities laws by providing false or misleading information to investors [3]

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Hims & Hers Health is set to offer generic semaglutide in Canada as Novo Nordisk's patent on Ozempic and Wegovy is expiring in January [1][2] - The company aims to provide affordable and high-quality weight loss care, emphasizing accessibility and personalized care [2] - The Canadian semaglutide market generated $1.18 billion in 2024 and is projected to grow to $4.03 billion by 2035 [4] Company Strategy - Hims & Hers is entering the Canadian market for the first time, joining other drugmakers capitalizing on the expired patent of GLP-1 drugs [2] - The company is collaborating with an approved partner to ensure compliance with local laws and regulations regarding the generic semaglutide [5] Market Context - Generic semaglutide is a copy of the brand-name drugs Ozempic and Wegovy, offering the same efficacy and safety standards once the patent expires [3] - The approval process for generic semaglutide is underway in Canada, although no generic version has been approved yet [4][5]

癌症乃是悬于当今人类健康之上的达摩克利斯之剑。时至今日，人们依然谈"癌"色变。 世界卫生组织下属的国际癌症研究机构最近发布的一份调查研究显示，预计到2050年，全球癌症新发将 超过3500万例，与2022年相比猛增77%。而吸烟、喝酒、肥胖和空气污染是癌症发病率上升的关键因 素。 抗癌药物的研发史，也是一部人类与癌细胞"斗智斗勇"的进化史。然而，现有药物常常面临"杀敌一 千，自损八百"的困境：化疗的广泛毒性、靶向药的耐药性、免疫疗法的响应率瓶颈，无不提示着我们 需要更精准、更有效的打击策略。 癌细胞为了维持其疯狂的增殖，对能量和营养物质有着异乎寻常的贪婪需求。能否在满足正常细胞需求 的前提下，精准切断癌细胞的"生命补给线"？这正是香港理工大学梁润松教授团队研究的核心。他们揭 示了一种前所未有、极具选择性的"饿死癌细胞"机制，这种机制有望绕开传统疗法的诸多弊端，开辟一 条抗癌新路。 "我们不再局限于追踪单一靶点，而是寻找各类癌细胞及不同癌症类型的共性本质。我们的研究发现， 快速增殖的癌细胞对营养的需求显著提升，尤其依赖某些特定氨基酸作为代谢能量来源。"梁润松在接 受南方财经记者专访时表示。 十年磨一剑 大学时， ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, which contains the active ingredient semaglutide [3]. - Allegations include that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk and claimed compliance with FDA regulations regarding the sale of compounded semaglutide [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, and the lead plaintiff deadline is August 25, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its effectiveness in representing clients [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings of compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [4]

PHILADELPHIA, July 7, 2025 /PRNewswire/ -- Berger Montague, a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).Investor Deadline: Investors who purchased or acquired Hims & Hers securities between April 29, 2025 and June 22, 2025 (the "Class Period") may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.O ...